首页 | 本学科首页   官方微博 | 高级检索  
     


Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma.
Authors:C. L. Collins   N. G. Ordonez   R. Schaefer   C. D. Cook   S. S. Xie   J. Granger   P. L. Hsu   L. Fink     S. M. Hsu
Affiliation:Department of Pathology, University of Arkansas for Medical Sciences, Little Rock.
Abstract:Thrombomodulin (TM) is a glycoprotein of molecular weight 75,000 kd that is normally present in restricted numbers of cells, including endothelial and mesothelial cells. In this study, the authors tested the possibility of using anti-TM to facilitate the diagnosis of mesothelioma. All of the 31 mesotheliomas and the two mesothelioma cell lines (MS-1 and MS-2) tested were stained positively with anti-TM. The specificity of anti-TM staining in mesothelioma cells was further confirmed by in situ hybridization of MS-1 cells with a TM-specific probe. The expression of TM in MS-1 cells was increased markedly when these cells were induced by 12-0-tetradecanyl phorbol 13-acetate (TPA) to differentiate. The expression of TM in mesothelioma cells, however, did not correlate with any particular phase of the cell cycle. In an attempt to differentiate pleural mesothelioma from pulmonary adenocarcinoma, the authors compared the expression of TM, carcinoembryonic antigen (CEA), and Leu M1 in these two types of tumors. Only four of 48 (8%) pulmonary adenocarcinomas were stained positively by antibodies to TM. Therefore, immunohistochemical staining with antibodies to TM yielded 100% sensitivity and 92% specificity for diagnosis of mesothelioma. All of the mesotheliomas stained negatively for CEA and Leu M1, except for one, which showed minimal focal positivity for Leu M1. In contrast, 79% and 60% of adenocarcinomas stained positively for CEA and Leu M1, respectively. These findings suggest that immunocytochemical staining with anti-TM should be added to the battery of tests to increase the diagnostic sensitivity and specificity for differentiating mesothelioma from pulmonary adenocarcinoma.
Keywords:
正在获取引用信息，请稍候...
相似文献(共20条):
[1]、R.L. ATTANOOS,R. WEBB,& A.R. GIBBS.CD44H expression in reactive mesothelium, pleural mesothelioma and pulmonary adenocarcinoma[J].Histopathology,1997,30(3):260-263.
[2]、Frey AB,Wali A,Pass H,Lonardo F.Osteopontin is linked to p65 and MMP-9 expression in pulmonary adenocarcinoma but not in malignant pleural mesothelioma[J].Histopathology,2007,50(6):720-726.
[3]、Allen TC,Moran C.Synchronous pulmonary carcinoma and pleural diffuse malignant mesothelioma[J].Archives of pathology & laboratory medicine,2006,130(5):721-724.
[4]、T Kawai,M Suzuki,C Torikata,Y Suzuki.Expression of blood group-related antigens and Helix pomatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma[J].Human pathology,1991,22(2):118-124.
[5]、T. Kawai, S. D. Greenberg, L. D. Truong, C. A. Mattioli, M. Klima, and,J. L. Titus.Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.[J].The American journal of pathology,1988,130(2):401-410.
[6]、Cappia S,Righi L,Mirabelli D,Ceppi P,Bacillo E,Ardissone F,Molinaro L,Scagliotti GV,Papotti M.Prognostic role of osteopontin expression in malignant pleural mesothelioma[J].American journal of clinical pathology,2008,130(1):58-64.
[7]、Hirano H,Takeda S,Sawabata Y,Okumura Y,Maeda H,Hanibuchi M,Ito M,Nakagawa M,Uematsu K.Localized pleural malignant mesothelioma[J].Pathology international,2003,53(9):616-621.
[8]、Erkiliç S,Sari I,Tunçözgür B.Localized pleural malignant mesothelioma[J].Pathology international,2001,51(10):812-815.
[9]、P Tang,S K Vatsia,S Teichberg,E Kahn.Pulmonary adenocarcinoma simulating malignant mesothelioma.[J].Archives of pathology & laboratory medicine,2001,125(12):1598-1600.
[10]、Tomoko Yamagishi,Nobukazu Fujimoto,Yosuke Miyamoto,Michiko Asano,Yasuko Fuchimoto,Sae Wada,Kenichi Kitamura,Shinji Ozaki,Hideyuki Nishi,Takumi Kishimoto.Brain metastases in malignant pleural mesothelioma[J].Clinical & experimental metastasis,2016,33(3):231-237.
[11]、Marcella Klima,Ferenc Gyorkey.Benign pleural lesions and malignant mesothelioma[J].Virchows Archiv : an international journal of pathology,1977,376(3):181-193.
[12]、David Rice.Surgery for malignant pleural mesothelioma[J].Annals of diagnostic pathology,2009,13(1):65-72.
[13]、Li T,Hou SC,Mao JH,Wang YC,Lu XD,Tan JL,You B,Liu YP,Ni J,Au A,Jablons DM,Xu Z,You L.The expression of Dishevelled-3 and glutamine metabolism in malignant pleural mesothelioma[J].Journal of clinical pathology,2012,65(9):855-858.
[14]、莫世贤,邓勇军,刘焕鹏,李珏,陈理军,赵金燕,张良.Fibulin-3表达对恶性胸膜间皮瘤细胞的影响[J].中国病理生理杂志,2019,35(3):448-453.
[15]、Kaarteenaho-Wiik R,Soini Y,Pöllänen R,Pääkkö P,Kinnula VL.Over-expression of tenascin-C in malignant pleural mesothelioma[J].Histopathology,2003,42(3):280-291.
[16]、M Stochaj.A case of pleural malignant mesothelioma[J].Patologia polska,1969,20(3):341-347.
[17]、刘汉忠,肖静,涂珍,肖兰,杨继洲,王岚.胸腔镜胸膜活组织检查联合免疫组织化学诊断恶性胸腔间皮瘤[J].国际病理科学与临床杂志,2013(6):486-490.
[18]、A. KONDI-PAPHITIS,B.J. ADDIS.Secretory component in pulmonary adenocarcinoma and mesothelioma[J].Histopathology,1986,10(12):1279-1287.
[19]、喻朝霞,郑晓刚,夏思钧,孟奎,陆珍风,马恒辉,周晓军.间皮相关抗体在胸膜恶性间皮瘤和胸膜转移癌鉴别诊断中的作用[J].临床与实验病理学杂志,2004,20(4):428-431.
[20]、Betta PG,Magnani C,Bensi T,Trincheri NF,Orecchia S.Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma[J].Archives of pathology & laboratory medicine,2012,136(3):253-261.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号